Men with prostate cancer who consumed green tea prior to undergoing prostatectomy had reductions in markers of inflammation, say researchers from UCLAâ€™s David Geffen School of Medicine.
MRI-guided TULSA effective for managing localized prostate cancer
“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
Urine-based test demonstrates consistent efficacy in NMIBC surveillance
The Bladder EpiCheck test received FDA 510(k) clearance in May 2023 for use in patients with NMIBC.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Nadofaragene firadenovec efficacy in NMIBC sustained with extended follow-up
At 36 months’ follow-up the gene therapy nadofaragene firadenovec demonstrated durable complete responses in patients with high-risk, BCG-unresponsive non-muscle–invasive bladder cancer.
FDA grants priority review to frontline enfortumab vedotin plus pembrolizumab for urothelial carcinoma
The priority review is based on results from the phase 3 EV-302 trial.
2 Clarke Drive Cranbury, NJ 08512